Theravance Biopharma (TBPH) Cash & Current Investments (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Cash & Current Investments data on file, last reported at $394.7 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $394.7 million, up 201.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $394.7 million (up 201.61% YoY), and the FY2025 annual result was $170.2 million, up 92.63% from the prior year.
• Cash & Current Investments advanced to $394.7 million in Q1 2026 per TBPH's latest filing, from $170.2 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $486.8 million in Q3 2022 and troughed at $88.4 million in Q4 2024.
• A 5-year average of $195.7 million and a median of $147.5 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments slumped 72.47% in 2023, then surged 252.63% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $327.5 million in 2022, then sank by 68.72% to $102.4 million in 2023, then declined by 13.74% to $88.4 million in 2024, then surged by 92.63% to $170.2 million in 2025, then surged by 131.9% to $394.7 million in 2026.
• Business Quant data shows TBPH's Cash & Current Investments at $394.7 million in Q1 2026, $170.2 million in Q4 2025, and $177.2 million in Q3 2025.